Item 5.07 Submission of Matters to a Vote of Security Holders.

At the annual meeting of stockholders on December 18, 2019, Predictive Oncology Inc.'s (the "Company") stockholders took the following actions:

(i) The stockholders elected one Class I member, Thomas J. McGoldrick, to the


     Board of Directors by a plurality of the votes. There were 444,931 votes cast
     for Mr. McGoldrick and 824,500 withheld.

(ii) The stockholders did not approve a non-binding advisory resolution to


      approve compensation of the Company's executive officers. There were 429,964
      votes for the proposal; 838,882 votes against; 585 votes abstained; and
      there were 918,671 broker non-votes.

(iii) The stockholders did not approve an Amended and Restated 2012 Stock


       Incentive Plan, including an increase in the reserve of shares of common
       stock authorized for issuance thereunder by 600,000 to 1,600,000. There
       were 409,432 votes for the proposal; 846,354 votes against; 13,645 votes
       abstained; and there were 918,671 broker non-votes.

(iv) The stockholders ratified the appointment of Deloitte & Touche LLP as the

Company's registered public accounting firm for the fiscal year ending

December 31, 2019. There were 2,129,820 votes for the proposal; 56,235 votes

against; and 2,047 votes abstained.

© Edgar Online, source Glimpses